STELLA PHARMA CORPORATION
4888 | T
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Japan
- Address:
- 大阪市中央区高麗橋三丁目２番７号 ＯＲＩＸ高麗橋ビル
- Website:
- https://stella-pharma.co.jp/
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
STELLA PHARMA CORPORATION is a Japanese pharmaceutical company dedicated to advancing healthcare through the development of innovative medical products. Focused on Boron Neutron Capture Therapy (BNCT), the company aims to enhance treatment options, particularly for head and neck cancers. STELLA PHARMA actively engages in educational initiatives, such as organizing seminars for medical professionals and participating in industry conferences to disseminate knowledge about BNCT. The company is committed to contributing to the medical community and improving patient outcomes through cutting-edge research and collaboration with industry partners.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-26 07:06 |
Regulatory News Service
確認書
|
Japanese | 8.1 KB | |
| 2025-06-26 07:05 |
Annual Report
有価証券報告書－第18期(2024/04/01－2025/03/31)
|
Japanese | 1.2 MB | |
| 2025-06-26 07:05 |
Internal Control over Financial Reporting
内部統制報告書－第18期(2024/04/01－2025/03/31)
|
Japanese | 21.7 KB | |
| 2025-06-25 06:52 |
Inside Information Statement
臨時報告書
|
Japanese | 21.4 KB | |
| 2024-11-12 05:07 |
Regulatory News Service
確認書
|
Japanese | 8.1 KB | |
| 2024-11-12 05:06 |
Interim Report
半期報告書－第18期(2024/04/01－2025/03/31)
|
Japanese | 192.3 KB | |
| 2024-07-01 02:34 |
Inside Information Statement
臨時報告書
|
Japanese | 28.0 KB | |
| 2024-06-28 07:05 |
Internal Control over Financial Reporting
内部統制報告書－第17期(2023/04/01－2024/03/31)
|
Japanese | 21.3 KB | |
| 2024-06-28 07:04 |
Regulatory News Service
確認書
|
Japanese | 8.1 KB | |
| 2024-06-28 07:04 |
Annual Report
有価証券報告書－第17期(2023/04/01－2024/03/31)
|
Japanese | 1.1 MB | |
| 2024-02-14 05:13 |
Quarterly Report
四半期報告書－第17期第3四半期(2023/10/01－2023/12/31)
|
Japanese | 145.0 KB | |
| 2024-02-14 05:13 |
Regulatory News Service
確認書
|
Japanese | 8.1 KB | |
| 2023-11-14 06:08 |
Regulatory News Service
確認書
|
Japanese | 8.1 KB | |
| 2023-11-14 06:07 |
Quarterly Report
四半期報告書－第17期第2四半期(2023/07/01－2023/09/30)
|
Japanese | 172.5 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
EQL Pharma AB | Sweden | EQL | |
| E.S. Australia Israel Holdings LTD | Israel | AUIS | ||
|
EuroAPI | France | EAPI | |
|
Eurofins-Cerep | France | ALECR | |
|
EUROPEAN GREEN TRANSITION PLC | United Kingdom | EGT | |
|
Evolear AB | Sweden | EVOL | |
|
Faes Farma S.A. | Spain | FAE | |
|
Fagron N.V. | Belgium | FAGR | |
|
Farmak | Ukraine | FARM | |
|
Farmsintez ao | Russian Federation | LIFE |